Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122978513 | 12297851 | 3 | F | 20121001 | 20160701 | 20160422 | 20160706 | EXP | NL-PFIZER INC-2015299986 | PFIZER | 40.00 | YR | M | Y | 0.00000 | 20160706 | CN | NL | NL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122978513 | 12297851 | 1 | PS | SOMAVERT | PEGVISOMANT | 1 | 40 MG, WEEKLY (1X/WEEK) | 21106 | 40 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||||
| 122978513 | 12297851 | 2 | SS | SOMAVERT | PEGVISOMANT | 1 | 60 MG, WEEKLY (1X/WEEK) | 21106 | 60 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||||
| 122978513 | 12297851 | 3 | SS | SOMAVERT | PEGVISOMANT | 1 | 60 MG, WEEKLY (1X/WEEK) | 21106 | 60 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||||
| 122978513 | 12297851 | 4 | SS | SOMAVERT | PEGVISOMANT | 1 | 20 MG, 3X/WEEK | 21106 | 20 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | ||||||||
| 122978513 | 12297851 | 5 | SS | SOMAVERT | PEGVISOMANT | 1 | Subcutaneous | 80 MG, WEEKLY (1X/WEEK) | 21106 | 80 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | ||||||
| 122978513 | 12297851 | 6 | SS | SOMAVERT | PEGVISOMANT | 1 | 100 MG, 1X/WEEK | 21106 | 100 | MG | POWDER AND SOLVENT FOR SOLUTION FOR INJECTION | /wk | |||||||
| 122978513 | 12297851 | 7 | C | FLIXONASE | FLUTICASONE PROPIONATE | 1 | 0.4 MG, 2X/DAY (IN BOTH NOSE NOSTRILS) | 0 | .4 | MG | NASAL DROPS | BID | |||||||
| 122978513 | 12297851 | 8 | C | CABERGOLINE SANDOZ | CABERGOLINE | 1 | 1 MG (2 TABLETS OF 0.5 MG), 5X/WEEK | 0 | 1 | MG | TABLET |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122978513 | 12297851 | 1 | Acromegaly |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122978513 | 12297851 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122978513 | 12297851 | Abdominal pain | |
| 122978513 | 12297851 | Drug ineffective | |
| 122978513 | 12297851 | Fatigue | |
| 122978513 | 12297851 | Haematochezia | |
| 122978513 | 12297851 | Muscle spasms | |
| 122978513 | 12297851 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122978513 | 12297851 | 1 | 20121001 | 0 | ||
| 122978513 | 12297851 | 2 | 20121026 | 0 | ||
| 122978513 | 12297851 | 3 | 20121123 | 0 | ||
| 122978513 | 12297851 | 5 | 20160414 | 20160701 | 0 | |
| 122978513 | 12297851 | 6 | 20160702 | 0 |